Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Date:11/7/2012

press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

  

Keryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts) Statements of Operations Information (Unaudited):Three Months Ended September 30,Nine Months Ended September 30,2012201120122011REVENUE:License revenue$
--$
--$
--$
5,000OPERATING EXPENSES:Research and development:Non-cash compensation

161

152

512

616Other research and development

3,768

8,620

14,616

19,533Total research and development

3,929

8,772

15,128

20,149General and administrative:Non-cash compensation

384

320

1,117

948Other general and administrative

1,213

1,263

4,156

3,951Total general and administrative

1,597

1,583

5,273

4,899TOTAL OPERATING EXPENSES5,526

10,355

20,401

25,048OPERATING LOSS(5,526)

(10,355)

(20,401)

(20,048)OTHER INCOME:Interest and other income, net

51

108

1,669

300LOSS BEFORE EXTRAORDINARY GAIN(5,475)

(10,247)

(18,732)

(19,748)EXTRAORDINARY GAIN--

--

2
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
2. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
4. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Boston Childrens Hospital announces international genomics competition winner
7. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
8. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
9. AMRI Announces Third Quarter 2012 Results
10. Egenix, Inc. Announces New Director
11. BioRestorative Therapies Announces Stock Trading On OTC Bulletin Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... Intrexon Corporation (NYSE: XON ), a ... its previously announced public offering of common stock, including ... option to purchase an additional 731,707 shares of common ... share.  The exercise of the underwriters, option brought the ... Intrexon to 5,609,756 shares and increased the total gross ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... 29, 2011 USChina Channel LLC announced today: ... Inc. ("CBI") filed Form 8-k of SEC, to announce the ... process is going very well. We already have ... the vote. Followings are the interim vote results for the ...
... Morphotek®, Inc., a subsidiary of Eisai Inc., ... collaboration and license agreement with Biocare Medical, LLC. ... develop and commercialize an immunohistochemical (IHC) diagnostic kit ... human folate receptor alpha (FRA) with Biocare,s intelliPATH™ ...
... NEW YORK, March 29, 2011 Reportlinker.com ... is available in its catalogue: ... and Europe - Development and Approval of ... http://www.reportlinker.com/p0464103/Biosimilars-Approval-Pathways-in-the-US-and-Europe---Development-and-Approval-of-Biosimilar-mABs-May-Face-Tough-Regulatory-Environment.html ...
Cached Biology Technology:Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 2Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 2Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 3Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 4Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 5Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 6Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 7Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 8Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 9Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 10Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 11Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 12Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 13
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... BUFFALO, NY -- Exposure to air pollution early in ... child may alter her DNA and may be associated with ... at Buffalo have shown. The findings indicated that higher ... may increase levels of E-cadherin, a protein important to the ...
... won $100 and then offered you a few dollars, would ... be, sure, why not? "But human decision making does not ... Virginia Tech and director of the Human Neuroimaging Laboratory at ... research conducted over the last three decades; only about one-fourth ...
... of the Deepwater Horizon oil spill that took the lives ... of coastal Louisiana, it,s difficult to put the complicated relationship ... have thus far not been as pervasive as originally feared, ... too early to tell. However, dependence upon oil has not ...
Cached Biology News:Air pollution exposure affects chances of developing premenopausal breast cancer 2Functional MRI shows how mindfulness meditation changes decision-making process 2Functional MRI shows how mindfulness meditation changes decision-making process 3Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 2Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 3Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 4Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 5
... Features, Special optically clear polystyrene formulation ... in immunoassay applications , Plates are ... coefficients of variation , Eight-well strips ... strip loss while in use even if ...
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
Biology Products: